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ABSTRACT 
 
 Pharmacovigilance refers to the process of identifying, detecting, and responding to drug 
safety issue and has witnessed dynamic advancements in pharmaceutical industries 
throughout the world. The main objective of pharmacovigilance is to extend the safety 
monitoring and to detect any ADRs that previously got unrecognized in evolution during 
clinical trial. ADRs monitoring is required for each medicine throughout its lifecycle which 
includes early stage of drug design, clinical trials, and post marketing surveillance. The 
emerging trend in pharmacovigilance is to link the pre marketing data with the data collected 
during post marketing phase that include safety information. India is a vast country with 
population of over 1.32 Billion with different social economics status, different patterns of 
disease prevalence it becomes more important to have a standardized and robust 
pharmacovigilance. Pharmacists, as doctor remark that their involvement may increase the 
reporting rate and have a greater role to play in the area of pharmacovigilance 
Introduction
The word pharmacovigilance (PV) was introduced in mid-70s 
by a group of French toxicologists and pharmacologist to 
explain the activities that promotes “The assessment of the 
risks of side effects potentially associated with drug 
treatment” [1]. The term originated from Greek word 
“Pharmakon” means drug and “vigilare” refers to watch. The 
increasing issue of Adverse Drug Reactions related to drug 
leads the development of a new branch in pharmacological 
science known as Pharmacovigilance [2]. PV is defined as the 
science and activities relating to detection, evaluation, 
understanding and prevention of adverse effects or ADR. It is 
the most important and integral part of clinical research and 
drug development. The main function of PV in the industry is 
almost same as those of regulatory agencies; that is to protect 
patient from unnecessary harm by detecting previously 
unrecognized drug hazards and quantifying risk in relation to 
benefits [3]. 
 
SCOPES OF PV 
 
The discipline of PV has shown a considerable development 
since the 1972 WHO technical report, and it remains a 
dynamic clinical and scientific discipline. Now it has become 
more important to meet the challenges of the increasing range 
and potency of pharmaceutical and biological medicines 
including all types of oral, tropical, parental (vaccine), which 
carry with them an inevitable and sometimes unpredictable 
potential harm. When toxicity or the adverse effect appear, 
especially when previously unknown , it is essential that they 
are analyzed and communicated effectively to mass population 
that has the knowledge to interpret the information. This is the 
role of PV, of which much has already been achieved but 
many more is required for integration of the discipline into 
clinical practice and public policy [4]. 
 
PHARMACEUTICAL MARKET OF WHOLE WORLD 
The pharmaceutical industry is comparised of companies that 
are engaged in researching, developing, manufacturing and 
distributing drugs for human as well as for veterinary use [5]. 
Pharmaceuticals are the 8th largest global product in import 
and export business. Mainly six types of products are included 
in pharmaceutical import export business all these came under 
following HS code- 3004, 3002, 3006, 3005, 3003 and 3001. 
The product under HS code 3004 (Medicaments consisting of 
mixed and unmixed products for therapeutic or prophylactic 
uses) are the most exported and imported pharmaceutical 
products. Germany is the largest exporter in the world 
followed by Switzerland, United States of America and 
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Belgium. Germany pharmaceutical exports represent 15.3% of 
total export. During the year 2016 Germany record 
pharmaceutical export of USD 77098405 thousand as per 
shown in (table 1). USA, UK and Neatherlands are in the list 
of top pharmaceutical importer countries [6]. Market research 
firm Evaluate pharma, through annual World Preview report, 
projects a global growth rate for the pharma industry of 6.3% 
CAGR through 2022 [7].  
 
Table 1: Exporter Country 
 
Exporter Country Value (USD Thousand) 
Germany 77098405 
Switzerland 67454988 
USA 47128898 
Belgium 41975129 
UK 32947770 
Ireland 31775741 
France 30126331 
Netherlands 28237527 
Italy 21215394 
India 13042726 
                                
Table 2: Importer Country 
 
Importer Country Value(USD Thousand) 
USA 92505408 
Germany 49096043 
Belgium 34891600 
UK 32747620 
Switzerland 24674012 
Japan 22067813 
France 21288771 
Netherlands 20971483 
China 20734931 
*above stats are based on report of 2016 
 
Pharmaceutical Market of INDIA 
 
The Indian pharmaceutical market is third largest in terms of 
volume and thirteen largest in term of value. The Indian 
pharmaceutical industry cover up about 20% market and it 
hold share value of about 1.4% of the Global Pharmaceutical 
Industry. India’s cost of production is approximately 33% less 
than that of the US. The growth rate of Indian pharmaceutical 
industry was ranged between 12-14 % till 2015 and now it is 
expected to grow over 15% per annum during year 2015-2020. 
According to Pharmaceuticals Export Promotion Council of 
India (PHARMEXCIL) the growth in export rate of 30% is 
expected in year of 2017 to 2020 [8]. This growth in 
pharmaceutical industry leads to emergence as a hub for 
clinical trials and drug discovery and development [9]. More 
and more drug entities are being introduced which includes 
New Chemical Entities, Pharma products, vaccines, dosage 
from, new routes of drug administration and new therapeutic 
claims of existing drug moieties. It is demonstrated in the fact 
that the total number of applications received and processed at 
CDSCO HQ; New Delhi has increased more than twice from 
10,000 in the year 2005 to 22,806 in year 2009 and is still 
increasing. This includes increase in New Drug Applications, 
Clinical Trials, Market Authorization of vaccines and biotech 
products [10]. All this leads to the monitoring of Adverse drug 
Reactions (ADRs) for pharmaceutical products over a large 
population base. Every drug have side effect but some remains 
unknown even through the drug is in clinical use. It is decisive 
to study the known and unknown side effects of the drug for 
better assessment of benefit-risk ratio of the drug. After the 
ban imposed by CDSCO on some of major drugs like 
dextropropoxyphene and analgin, pharmacovigilance has 
become an important asset for assessing the safety profile of 
the drugs. 
 
SCENARIO OF CLINICAL TRIAL AND REGULATION 
 
Most of the Global pharmaceutical companies have found 
India to be the better destination for the clinical trials because 
India’s clinical research space, facilities and opportunities are 
very attractive [11]. As per a recent report of Federation of 
Indian Chambers of Commerce and Industry (FICCI), 
scientific feasibility, medical infrastructure, commercialization 
potential, cost competitiveness, clinical trial experience, 
regulation are some of the drivers that are responsible for the 
metamorphosis of Indian Clinical Research growth in past few 
years. 
SWOT Analysis of Indian Clinical Trial Sector: 
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Strengths 
 
 Large population of over 1.32 billion, which is about 17% 
of world population. 
 Huge pharmaceutical and biotech industry base with mass 
number of skilled persons [4]. 
 Third largest country in the world with more than 500 
different active pharmaceutical ingredients [12]. 
 India’s cost of production is nearly 33 percent lower than 
that of the US. 
 Labour costs are 50 to 55% cheaper than the western 
countries. 
 Large data mining related to safety profile of drugs 
possibilities due to large population [13]. 
 
Opportunities 
 
 The Indian population is the world largest source of 
human biodiversity. 
 It consist of 4635 culturally and anthropologically well 
defined populations, expressing a perfect model for study 
of safety profile of drug, molecular pathology, etiology, 
disease susceptibility with respect to genetic diversity. 
 Excellent potential for skilled human resources needed for 
an  effective PV system because of mass number of 
recognized medical, dental, pharmacy and nursing college 
in India [14]. 
 
CASE STUDY ON POST MARKETING SURVILLENCE 
In spite of the fact that all drug goes through extensive 
screening before its approval by the food and Drug 
Administration (FDA), many ADRs may still be missed 
because of the clinical trials are often small, short, and biased 
by excluding patients with comorbid diseases. Since 
premarketing trial do not show the actual clinical use situation 
for diverse population, thus it is important to have post 
marketing surveillance. PV has the most important role in the 
analysis of newly produced drug in post marketing trail [15]. 
PV research is mainly based on the analysis of “signals”. The 
WHO defines signals as undisclosed assertions on the direct 
relationship between effects on the living body and a drug to 
induce adverse effect [16]. PV researchers are now facing 
problem of delivering knowledge-oriented tools and services 
that exploit the scope of collecting data. Lastly, the accurate 
exploration of these data will make the way of improved drug 
evaluations, critical for pharmaceutical companies [17]. 
 
FUTURE PROSPECTIVE 
The Indian pharmaceutical market size is expected to grow to 
US$ 100 billion by 2025, driven by raising healthcare 
facilities and PV system. PV systems are capable of detecting 
new ADRs and taking regulatory actions needed for protection 
of public health. The emphasis has been put into generating 
information that can assist a healthcare professional or a 
patient for making right decision. The communication and 
gathering of this information is the main goal of PV [17]. PV 
methods must also be able to describe to describe which 
patients are at risk of developing ADRs. As per the source of 
information the PV system would be consistent with the 
growing patient involvement in drug safety. At present DCGI 
is working effectively to improve PV so as to integrate Good 
Pharmacovigelance Practice (GPP) [18]. The very innovative 
tool and processes in PV will help to advance pharmaceutical 
industry to promoting detectation and analysis of ADRs by 
increasing efficiency and providing new analytical 
capabilities. 
 
Conclusion 
  
The PV in India continues to grow, evolve, and improve with 
time. India is emerging as an important clinical trial hub and 
the largest producer as well as exporter of pharmaceutical 
products in the world. Hence, the need for the professional 
specialization, a combined view on PGx and clinical 
requirements are needed which helps to identify the factors 
that increase the risk of unwanted result from drug therapy and 
prior to commencing the treatment. Data mining Technology 
is now part of PV. The PvPI is coordinated at IPC through 
NCC to generate an independent data on safety of medicines, 
which will be included in global drug safety monitoring 
standards. National and Regional PV systems are well adapted 
bodies for indicating the analysis of ADRs data that further 
leads to development of new and effective medical products 
which makes a positive contribution to health and well being 
of individuals. Hence, PV for medicinal product safety is a 
collective responsibility of drug regulators, industry and health 
professionals to ensure the well being of the patients. The 
financial support to PV system and the increasing clinical trial 
of drug product should help to achieve a more comprehensive 
PV activity in India. 
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